What Comes After Ozempic? - The Amylin Gambit: Novo's Bet on a Forgotten Hormone

What Comes After Ozempic? Next-Gen Weight Loss Drugs - Discover the future of medicine with Dr. Ben Synth

Join Dr. Ben Synth as he explores next-generation weight loss medications making Ozempic look like just the beginning. From triple-receptor drugs shattering clinical trial records to amylin becoming pharmaceutical gold, discover breakthrough treatments racing toward FDA approval—including the holy grail daily pill replacing injections forever. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

What Comes After Ozempic? - The Pill Race: Can an Oral Drug Kill the Needle?

Ben Synth explores whether pharmaceutical companies can create an oral obesity pill as effective as current injectable GLP-1 drugs. He examines promising candidates like Structure Therapeutics' aleniglipron and Novo Nordisk's oral amycretin, explaining why delivering peptides through pills is so chemically challenging and what breakthrough could mean for global access. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

What Comes After Ozempic? - The Amylin Gambit: Novo's Bet on a Forgotten Hormone

Ben Synth explores how Novo Nordisk is betting on amylin, a long-overlooked hormone, to create the next generation of obesity drugs. From CagriSema's 20% weight loss to amycretin's stunning 24% in just 36 weeks, these dual-action therapies could dethrone semaglutide by targeting appetite through complementary brain pathways—rewriting the obesity treatment playbook. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.

What Comes After Ozempic? - The Triple Threat: Retatrutide Rewrites the Playbook

Ben Synth explores retatrutide, Eli Lilly's triple-receptor weight loss drug showing 24% body weight reduction in phase 2 trials—potentially approaching bariatric surgery results. This episode examines the GLP-1, GIP, and glucagon receptor mechanisms, the ongoing TRIUMPH trials enrolling 5,800 participants, and whether this molecule represents the future of metabolic medicine or another cautionary tale. Loved this episode? Discover more original shows from the Quiet Please Network at QuietPlease.ai, explore our curated favorites here amzn.to/42YoQGI, and catch just a slice of our AI hosts in action on Instagram at instagram.com/claredelish and YouTube at youtube.com/@DIYHOMEGARDENTV This content was created in partnership and with the help of Artificial Intelligence AI.